Department of Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL, USA.
Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
J Asthma. 2020 Sep;57(9):1039-1041. doi: 10.1080/02770903.2019.1628252. Epub 2019 Jun 14.
: Azathioprine is an immune-modulating agent used in the management of autoimmune diseases and in preventing graft rejection. Its role in the management of refractory asthma is not very well-established.: A 47-year-old female with an underlying severe refractory asthma, managed with high dose steroids, was seen as an outpatient. Her course was complicated by frequent asthma exacerbation and severe adverse effects of chronic steroid use. Her symptoms did not respond to standard asthma management per Guidelines for the Diagnosis and Management of Asthma 1. She was tried on other management which included methotrexate and omalizumab injections without success. Azathioprine was started as a steroid-sparing agent following which her symptoms showed dramatic improvement with fewer exacerbations, higher peak flow measurements, and she was able to wean down her daily prednisone dose from 60 mg/day to 5 mg/day.: Azathioprine is still an investigational agent for the management of asthma and more research needs to be done to evaluate its role. To our knowledge, this is the second case report which details the therapeutic role of Azathioprine in the management of asthma.
: 硫唑嘌呤是一种免疫调节剂，用于治疗自身免疫性疾病和预防移植物排斥。其在难治性哮喘中的作用尚未得到充分确立。: 一名 47 岁女性患有严重的难治性哮喘，接受高剂量类固醇治疗，作为门诊患者就诊。她的病情因频繁的哮喘发作和慢性类固醇使用的严重不良反应而复杂化。她的症状对哮喘诊断和管理指南 1 中的标准哮喘管理没有反应。她尝试了其他管理方法，包括甲氨蝶呤和奥马珠单抗注射，但均未成功。在开始使用硫唑嘌呤作为类固醇节约剂后，她的症状显著改善，哮喘发作次数减少，峰值流量测量值升高，她能够将每日泼尼松剂量从 60mg/天减至 5mg/天。: 硫唑嘌呤仍然是一种用于哮喘管理的研究性药物，需要进行更多的研究来评估其作用。据我们所知，这是第二份详细阐述硫唑嘌呤在哮喘管理中的治疗作用的病例报告。
